An arrhythmia is a problem with the speed or rhythm of the heartbeat. During an arrhythmia, the heart can beat too fast, too slow, or with an irregular rhythm. A heartbeat that is too fast is called tachycardia. A heartbeat that is too slow is called bradycardia. Most arrhythmias are harmless, but some can be serious or even life threatening. When the heart rate is too slow, too fast, or irregular, the heart may not be able to pump enough blood to the body. Lack of blood flow can damage the brain, heart, and other organs.
Merck today announced that final results from two pivotal Phase III studies of boceprevir, its investigational oral hepatitis C protease inhibitor, will be presented in oral plenary sessions at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), which is taking place from Oct. 29 through Nov. 2 in Boston. Results for boceprevir in response-guided therapy strategies, which evaluated treatment durations shorter than current standard therapy, will be presented during the meeting.
Global Health Partner (STO:GHP) has acquired Stockholm Gastro Center, a specialist clinic with operations within medical gastroenterology and endoscopy located at Sophiahemmet in Stockholm. "The acquisition of Stockholm Gastro Center is a good complement to the obesity surgery business that we run at Kirurgkliniken and Bariatric Center Stockholm in Sophiahemmet's facilities. This is a combination of businesses that we also have at our clinics in Lund and Prague and where we see good coordination and expansion opportunities," says Per Båtelson, Global Health Partner's CEO.
During the recent Atrial Fibrillation Session of the Techno College at the European Association of Cardiac Thoracic Surgeons in Geneva, Switzerland, Professor Borut Gersak, Head of Cardiac Surgery from University Medical Center in Ljubljana, Slovenia challenged his audience of more than 1,000 medical professionals to think differently about existing atrial fibrillation surgical approaches.
Patients under age 45 had fewer major complications than older patients and comparable improvement after a medical procedure to treat irregular heartbeat, or arrhythmia, in a study reported in Circulation: Arrhythmia and Electrophysiology, an American Heart Association journal.
Stereotaxis, Inc. today announced that the U.S. Patent and Trademark Office granted the Company its 100th patent, a major intellectual property milestone. The 100th patent, U.S. patent No. 7,772,950, covers the "Method and Apparatus for Dynamic Magnetic Field Control Using Multiple Magnets." The 100th patent reflects Stereotaxis' ongoing commitment to innovate and protect its leading position in robotic solutions for interventional medicine.
An abrupt, fatal heart attack in a young athlete on the playing field is a tragedy destined to repeat itself over and over until more is understood about hypertrophic cardiomyopathy (HCM), a genetic disorder that is the most common cause of sudden death in young people but which affects people of all ages.
Relypsa, Inc., a biopharmaceutical company developing non-absorbed polymeric drugs, today announced positive results from the company's PEARL-HF study, a Phase 2 clinical trial of the company's lead compound, RLY5016. These data were presented by Dr. Bertram Pitt, Professor of Medicine Emeritus, Division of Medicine at the University of Michigan School of Medicine, during the Late-Breaking Clinical Trials Session in an oral presentation titled "The PEARL-HF (Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multiple-Dose To Evaluate the Effects of RLY5016 in Heart Failure Patients) Trial" at the 14th Annual Scientific Meeting of the Heart Failure Society of America held in San Diego, CA September 13-15, 2010.
An abrupt, fatal heart attack in a young athlete on the playing field is a tragedy destined to repeat itself over and over until more is understood about hypertrophic cardiomyopathy (HCM), a genetic disorder that is the most common cause of sudden death in young people but which affects people of all ages. So says a task force of cardiologists and cardiac biologists, headed by Thomas L. Force, M.D., James C. Wilson Professor of Medicine at Thomas Jefferson University, in the September 14th online edition of the journal Circulation.
Medtronic, Inc. today introduced the CareLink® Network for Heart Failure, an extension of the world's largest remote implantable cardiac device monitoring system, that will be available this fall for heart failure clinicians.
Stereotaxis, Inc. highlighted significant new additions to the body of evidence demonstrating exceptional clinical outcomes achieved with its Niobe® Magnetic Navigation System in ventricular tachycardia ablation.
The National Institutes of Health plans to spend $161.3 million over the next five years to expand the Pharmacogenomics Research Network (PGRN), a nationwide collaborative of scientists focused on understanding how genes affect a person's response to medicines.
MSD and Cardiome Pharma Corp. today announced that the intravenous (IV) formulation of BRINAVESS™ (vernakalant) has been granted marketing approval in the European Union (EU), Iceland and Norway for the conversion of recent onset atrial fibrillation (AF) to sinus rhythm in adults.
The European Society of Cardiology (ESC) today announces the release of new Clinical Practice Guidelines covering Atrial Fibrillation. These are the first guidelines to be prepared solely by the ESC on this very important topic.
Atrial fibrillation (AF) is the most common cardiac arrhythmia, affecting about 7 million people in Europe. It is a progressive chronic disease in which episodes become more frequent and long-lasting over time. Conventional anti-arrhythmic therapy aims at halting progression and reducing symptoms, but the use of most anti-arrhythmic drugs is compromised by severe side effects, such as pro-arrhythmia or extra-cardiac organ toxicity.
Royal Philips Electronics today announced the enhanced iE33 xMATRIX cardiac ultrasound system featuring a new ergonomic solution for more efficient adult echocardiograms, the X5-1 transducer. With this enhanced technology, Philips continues its tradition of simplified, patient-focused healthcare solutions by providing a more complete imaging solution.
Mobile Health Expo, the only event focusing on the convergence of mobile technology and healthcare across the entire mobile health ecosystem, today revealed some highlights from the conference program that focuses on the truly international nature of mobile health. Speakers representing both developing and developed nations will share case studies and best practices of how mobile health is being used in other countries.
Results from the Alpha Omega Trial, a multicentre, placebo-controlled trial in men and women following myocardial infarction (MI), suggest that low doses of n-3 fatty acids given in the form of enriched margarines do not reduce the overall rate of major cardiovascular events.
Results from a recent phase 2b clinical trial may provide a new approach to managing excess potassium levels in patients with heart failure and heart failure with chronic kidney disease.
Medtronic, Inc. today announced it received Health Canada approval for the Medtronic Ablation Frontiers Cardiac Ablation System, a novel radiofrequency ablation technology for the treatment of atrial fibrillation. AF is the most common heart arrhythmia that affects more than 250,000 Canadians and seven million people worldwide.
Bristol-Myers Squibb Company and Pfizer report that preliminary results from the Phase 3 AVERROES clinical trial of the investigational drug apixaban compared with acetylsalicylic acid (ASA, or aspirin) in patients with atrial fibrillation expected to be or demonstrated to be unsuitable for warfarin therapy will be presented at the European Society of Cardiology Congress 2010. The results will be presented during the "Hot Line" session on August 31, 2010, in Stockholm, Sweden.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.